NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 237 filers reported holding NEKTAR THERAPEUTICS in Q1 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $480,000 | -60.8% | 89,000 | -1.9% | 0.00% | -50.0% |
| Q4 2021 | $1,225,000 | -0.9% | 90,700 | +30.8% | 0.01% | -11.1% |
| Q3 2021 | $1,236,000 | +22.5% | 69,321 | +16.9% | 0.01% | +12.5% |
| Q2 2021 | $1,009,000 | -21.5% | 59,321 | -7.7% | 0.01% | -33.3% |
| Q1 2021 | $1,286,000 | +26.5% | 64,300 | +7.5% | 0.01% | +20.0% |
| Q4 2020 | $1,017,000 | +5.2% | 59,800 | +2.6% | 0.01% | -9.1% |
| Q3 2020 | $967,000 | -33.3% | 58,300 | -6.8% | 0.01% | -38.9% |
| Q2 2020 | $1,449,000 | +29.7% | 62,550 | 0.0% | 0.02% | +12.5% |
| Q1 2020 | $1,117,000 | -7.7% | 62,550 | +11.6% | 0.02% | +23.1% |
| Q4 2019 | $1,210,000 | +296.7% | 56,050 | +553.6% | 0.01% | +225.0% |
| Q3 2019 | $305,000 | 0.0% | 8,575 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $305,000 | +7.0% | 8,575 | +1.2% | 0.00% | 0.0% |
| Q1 2019 | $285,000 | – | 8,475 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |